[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Pharvaris N.V. (PHVS)

Pharvaris N.V. (PHVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,420,096
  • Shares Outstanding, K 65,408
  • Annual Sales, $ 0 K
  • Annual Income, $ -198,790 K
  • EBIT $ -213 M
  • EBITDA $ -212 M
  • 60-Month Beta -2.31
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.92

Options Overview Details

View History
  • Implied Volatility 138.66% (+10.96%)
  • Historical Volatility 45.50%
  • IV Percentile 90%
  • IV Rank 65.39%
  • IV High 188.16% on 11/10/25
  • IV Low 45.16% on 08/26/26
  • Expected Move (DTE 21) 8.23 (23.30%)
  • Put/Call Vol Ratio 0.18
  • Today's Volume 148
  • Volume Avg (30-Day) 1,362
  • Put/Call OI Ratio 2.16
  • Today's Open Interest 30,940
  • Open Int (30-Day) 16,039
  • Expected Range 27.09 to 43.55

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.84
  • Number of Estimates 5
  • High Estimate $-0.77
  • Low Estimate $-0.92
  • Prior Year $-0.70
  • Growth Rate Est. (year over year) -20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
31.51 +12.09%
on 08/03/26
38.13 -7.37%
on 08/24/26
+1.67 (+4.98%)
since 07/28/26
3-Month
28.46 +24.10%
on 06/02/26
38.13 -7.37%
on 08/24/26
+5.46 (+18.29%)
since 05/28/26
52-Week
20.65 +71.04%
on 10/17/25
38.13 -7.37%
on 08/24/26
+12.48 (+54.64%)
since 08/28/25

Most Recent Stories

More News
Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update

ZUG, Switzerland, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs...

PHVS : 35.32 (-4.54%)
Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology

People with AAE-C1INH experience frequent misdiagnoses, emergency medical events, and wide-ranging impact on physical, emotional, and social...

PHVS : 35.32 (-4.54%)
Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema

Provides a state-of-the-art overview of the evidence on the critical role of bradykinin B2 receptor in the pathogenesis of bradykinin-mediated...

PHVS : 35.32 (-4.54%)
Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks

If approved, deucrictibant will be the first oral bradykinin B2 receptor antagonist to treat HAE attacksNDA includes positive data from successful clinical...

PHVS : 35.32 (-4.54%)
Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026

Results from prespecified assessment of End of Progression™ in the RAPIDe-3 Phase 3 study and clinical relevance of this newly-defined endpoint detailed in...

PHVS : 35.32 (-4.54%)
Pharvaris Announces Annual General Meeting of Shareholders

ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2...

PHVS : 35.32 (-4.54%)
Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026

ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2...

PHVS : 35.32 (-4.54%)
Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update

Topline data from CHAPTER-3, a pivotal Phase 3 study of deucrictibant XR for the prophylaxis of HAE attacks, expected in 3Q2026Timeline for submission of...

PHVS : 35.32 (-4.54%)
Pharvaris Reports Earnings Days After Pricing a Hundred Million Dollar Offering

Barchart Research What to Expect from PHVS Earnings PHVS Generated May 11, 2026 Current Price $30.00 EPS Estimate $$-0.76 Consensus Rating Strong Buy Average Move 4.91% Pharvaris Reports Earnings Days...

PHVS : 35.32 (-4.54%)
Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares

ZUG, Switzerland, May 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel,...

PHVS : 35.32 (-4.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Pharvaris N.V. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative therapies, including novel, small molecule bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema and other bradykinin-B2-receptor-mediated...

See More

Key Turning Points

3rd Resistance Point 38.88
2nd Resistance Point 38.14
1st Resistance Point 36.73
Last Price 35.32
1st Support Level 34.58
2nd Support Level 33.85
3rd Support Level 32.44

See More

52-Week High 38.13
Last Price 35.32
Fibonacci 61.8% 31.45
Fibonacci 50% 29.39
Fibonacci 38.2% 27.33
52-Week Low 20.65

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.